Additionally, loss of muscle mass during rapid weight loss can reduce the efficiency of muscle pumps that help return blood from the extremities to the heart, leading to blood stasis, particularly in the legs, which is a risk factor for deep vein thrombosis (DVT)
Severity of Pigmentation: Mild or superficial dullness may respond differently compared to deeper or long-standing hyperpigmentation
20 How results (e.g., weight loss, glycemic control, etc.) and tolerability (i.e., side effects) compare to current FDA-approved GLP1 and GLP1/GIP receptor agonists remain to be seen
Smaller Biotechs and Collaborators: Companies like Zealand Pharma, Glycadia, and others have GLP-1 analogs or co-agonists in early trials, often in partnership with larger pharma (e.g., Novo Nordisk collaboration with Zealand)
Not sure which BPC-157 or TB-500 protocol fits your recovery goal